

Claims

1           1.     A method of treating spastic disorders, said method comprising  
2     administering to a subject having a spastic disorder a therapeutically effective  
3     amount of the compound gamma-aminobutyramide, analogs, substituted forms,  
4     derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs  
5     thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a  
6     metabolite, or a by-product.

1           2.     A method according to claim 1, wherein said administering step  
2     further comprises intrathecally delivering the compound.

1           3.     A method according to claim 1, wherein said administering step  
2     further comprises intraventricularly delivering the compound.

1           4.     A method according to claim 1, wherein the compound which  
2     yields gamma-aminobutyramide as a solubility product comprises 4-[[(4-  
3     chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylene]amino] butanamide.

1           5.     A method according to claim 1, wherein said administering step  
2     further comprises delivering the compound to the subject through an implantable  
3     pump.

10445328-01502

1           6.     A method according to claim 1, wherein said administering step  
2     further comprises delivering the compound to the subject through a spinal catheter.

1           7.     A method according to claim 1, wherein the spastic disorder is  
2     spastic hypertonia.

1           8.     A method according to claim 1, wherein the spastic disorder is  
2     dystonia.

1           9.     A method according to claim 1, wherein the spasticity or spastic  
2     disorder is caused by traumatic brain injury.

1           10.    A method according to claim 2, wherein said intrathecal delivering  
2     step comprises delivering the compound through a spinal catheter inserted in a  
3     substantially cephalid spinal location.

1           <sup>✓</sup>11.    A method for treating convulsions, said method comprising  
2     administering to a subject either having convulsions or predisposed to convulsions  
3     a therapeutically effective amount of the compound gamma-aminobutyramide,  
4     analog, substituted forms, derivatives, the pharmaceutically acceptable salts,  
5     esters, amides, and prodrugs thereof, or compounds which yield gamma-  
6     aminobutyramide as an intermediate, a metabolite, or a by-product.

10045320 "0311002  
20040909 09:25:40

1           12.    A method according to claim 11, wherein said administering step  
2           further comprises intrathecally delivering the compound.

1           13.    A method according to claim 11, wherein said administering step  
2           further comprises intraventricularly delivering the compound.

1           14.    A method according to claim 11, wherein the compound which  
2           yields gamma-aminobutyramide as a solubility product comprises 4-[(4-  
3           chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylene]amino] butanamide.

1           15.    A method according to claim 11, wherein said administering step  
2           further comprises delivering the compound to the subject through an implantable  
3           pump.

1           16.    A method according to claim 11, wherein said administering step  
2           further comprises delivering the compound to the subject through a catheter.

1           17.    A method according to claim 12, wherein said intrathecal  
2           delivering step comprises delivering the compound through a spinal catheter  
3           inserted in a substantially cephalid spinal location.

1           18.    A method for treating epilepsy, said method comprising  
2           intraventricularly administering a therapeutically effective amount of the

10049328 051502  
200150 02264001

3 compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the  
4 pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or  
5 compounds which yield gamma-aminobutyramide as an intermediate, a  
6 metabolite, or a by-product.

1 19. A method of treating pain, said method comprising administering  
2 to a subject having pain a therapeutically effective amount of the compound  
3 gamma-aminobutyramide, analogs, substituted forms, derivatives, the  
4 pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or  
5 compounds which yield gamma-aminobutyramide as an intermediate, a  
6 metabolite, or a by-product.

1 20. A method according to claim 19, wherein said administering step  
2 further comprises intrathecally delivering the compound.

1 21. A method according to claim 19, wherein said administering step  
2 further comprises intraventricularly delivering the compound.

1 22. A method according to claim 19, wherein the compound which  
2 yields gamma-aminobutyramide as a solubility product comprises 4-[[[4-  
3 chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylene]amino] butanamide.

1           23.    A method according to claim 19, wherein said administering step  
2    further comprises delivering the compound to the subject through an implantable  
3    pump.

1           24.    A method according to claim 19, wherein said administering step  
2    further comprises delivering the compound to the subject through a catheter.

1           25.    A method of treating idiopathic dystonia or torsional dystonia, said  
2    method comprising administering to a subject having idiopathic dystonia or  
3    torsional dystonia a therapeutically effective amount of baclofen.

1           26.    A method of treating idiopathic dystonia or torsional dystonia, said  
2    method comprising administering to a subject having idiopathic dystonia or  
3    torsional dystonia a therapeutically effective amount of gamma-aminobutyramide.

20250926 0540